Effectiveness of Colchicine for the Treatment of Long COVID

What is the effectiveness of 26-week oral colchicine therapy in improving functional outcomes among individuals with persistent symptoms after acute COVID-19 infection?In this randomized clinical trial including 346 adults, there was no statistically significant difference in functional capacity, respiratory function, mental states, constitutional symptoms, or inflammatory markers at 52 weeks among those treated with colchicine or placebo.This trial provides evidence against colchicine monotherapy as a broadly effective treatment for long COVID.

Corresponding Author: Niveditha Devasenapathy, PhD, MBBS, MSc, Academic Clinical Trials Unit, The George Institute for Global Health, India, 308, Third Floor, Elegance Tower, New Delhi, Delhi 110025, India (ndevasenapathy@georgeinstitute.org.in).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.